JP2014504646A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014504646A5 JP2014504646A5 JP2013552637A JP2013552637A JP2014504646A5 JP 2014504646 A5 JP2014504646 A5 JP 2014504646A5 JP 2013552637 A JP2013552637 A JP 2013552637A JP 2013552637 A JP2013552637 A JP 2013552637A JP 2014504646 A5 JP2014504646 A5 JP 2014504646A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- isopropoxy
- chloro
- medicament
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000004432 carbon atoms Chemical group C* 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- -1 propane-2-sulfonyl Chemical group 0.000 claims 3
- KTEIFNKAUNYNJU-GFCCVEGCSA-N Crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims 2
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims 2
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 229960005061 crizotinib Drugs 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000005842 heteroatoms Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- VERWOWGGCGHDQE-UHFFFAOYSA-N 5-chloro-2-N-(5-methyl-4-piperidin-4-yl-2-propan-2-yloxyphenyl)-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 claims 1
- BPMAKGFLDNAAQC-UHFFFAOYSA-N 6-[[5-chloro-4-(2-propan-2-ylsulfonylanilino)pyrimidin-2-yl]amino]-2-(1-methylpiperidin-4-yl)-5-propan-2-yloxy-3H-isoindol-1-one Chemical compound O=C1C=2C=C(NC=3N=C(NC=4C(=CC=CC=4)S(=O)(=O)C(C)C)C(Cl)=CN=3)C(OC(C)C)=CC=2CN1C1CCN(C)CC1 BPMAKGFLDNAAQC-UHFFFAOYSA-N 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 0 *c1ccccc1Nc1c(*)c(*)nc(Nc2c(*)cc(*)c(*)c2)n1 Chemical compound *c1ccccc1Nc1c(*)c(*)nc(Nc2c(*)cc(*)c(*)c2)n1 0.000 description 1
Claims (9)
- 式(I)において、R1がクロロである、請求項1に記載の医薬。
- 式(I)において、R4がイソプロポキシである、請求項1または2に記載の医薬。
- 式(I)において、R5およびR6が、それらが結合している炭素原子と一緒になって、−CH2−NR8−C(O)−を形成し、ここで、R8が水素または、C1〜6アルキルで置換されていてもよいピペリジニルである、
請求項1〜3のいずれかに記載の医薬。 - 該化合物が5−クロロ−N2−(2−イソプロポキシ−5−メチル−4−(ピペリジン−4−イル)フェニル)−N4−[2−(プロパン−2−スルホニル)−フェニル]−ピリミジン−2,4−ジアミンである、請求項1に記載の医薬。
- 該化合物が6−{5−クロロ−4−[2−(プロパン−2−スルホニル)−フェニルアミノ]−ピリミジン−2−イルアミノ}−5−イソプロポキシ−2−(1−メチル−ピペリジン−4−イル)−2,3−ジヒドロ−イソインドール−1−オンである、請求項1に記載の医薬。
- 該化合物が5−クロロ−N2−(2−イソプロポキシ−5−メチル−4−(ピペリジン−4−イル)フェニル)−N4−[2−(プロパン−2−スルホニル)−フェニル]−ピリミジン−2,4−ジアミンである、請求項7に記載の使用。
- 該化合物が6−{5−クロロ−4−[2−(プロパン−2−スルホニル)−フェニルアミノ]−ピリミジン−2−イルアミノ}−5−イソプロポキシ−2−(1−メチル−ピペリジン−4−イル)−2,3−ジヒドロ−イソインドール−1−オンである、請求項7に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161438878P | 2011-02-02 | 2011-02-02 | |
US61/438,878 | 2011-02-02 | ||
PCT/US2012/023669 WO2012106540A1 (en) | 2011-02-02 | 2012-02-02 | Methods of using alk inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014504646A JP2014504646A (ja) | 2014-02-24 |
JP2014504646A5 true JP2014504646A5 (ja) | 2014-07-24 |
JP5837095B2 JP5837095B2 (ja) | 2015-12-24 |
Family
ID=45582065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013552637A Active JP5837095B2 (ja) | 2011-02-02 | 2012-02-02 | Alk阻害剤の使用方法 |
Country Status (22)
Country | Link |
---|---|
US (1) | US8703787B2 (ja) |
EP (1) | EP2670401B1 (ja) |
JP (1) | JP5837095B2 (ja) |
KR (1) | KR101521861B1 (ja) |
CN (1) | CN103458881B (ja) |
AU (1) | AU2012212142B2 (ja) |
BR (1) | BR112013019643B1 (ja) |
CA (1) | CA2824092C (ja) |
CY (1) | CY1116662T1 (ja) |
DK (1) | DK2670401T3 (ja) |
EA (1) | EA023404B1 (ja) |
ES (1) | ES2543567T3 (ja) |
HR (1) | HRP20150946T1 (ja) |
HU (1) | HUE025395T2 (ja) |
ME (1) | ME02200B (ja) |
MX (1) | MX2013008791A (ja) |
PL (1) | PL2670401T3 (ja) |
PT (1) | PT2670401E (ja) |
RS (1) | RS54189B1 (ja) |
SI (1) | SI2670401T1 (ja) |
SM (1) | SMT201500300B (ja) |
WO (1) | WO2012106540A1 (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2917210B1 (en) | 2012-11-06 | 2019-02-27 | Shanghai Fochon Pharmaceutical Co. Ltd | Alk kinase inhibitors |
EP2916841A1 (en) * | 2012-11-07 | 2015-09-16 | Novartis AG | Combination therapy |
CN104109149B (zh) | 2013-04-22 | 2018-09-28 | 苏州泽璟生物制药有限公司 | 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物 |
ITMI20131124A1 (it) | 2013-07-04 | 2015-01-05 | Univ Milano Bicocca | 2-acilamminotiazoli per il trattamento del cancro |
WO2015003658A1 (en) * | 2013-07-11 | 2015-01-15 | Betta Pharmaceuticals Co., Ltd | Protein tyrosine kinase modulators and methods of use |
EP3038652B1 (en) * | 2013-08-28 | 2018-03-21 | Novartis AG | Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases |
CN104672214B (zh) * | 2013-12-03 | 2019-04-12 | 上海翰森生物医药科技有限公司 | 具有alk抑制活性的化合物及其制备与用途 |
US20160339023A1 (en) * | 2013-12-23 | 2016-11-24 | Fang Li | Pharmaceutical Combinations |
KR101656382B1 (ko) * | 2014-02-28 | 2016-09-09 | 한국화학연구원 | 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 |
CN104876914B (zh) * | 2014-02-28 | 2017-04-19 | 山东轩竹医药科技有限公司 | 嘧啶衍生物类间变性淋巴瘤激酶抑制剂 |
CN106459007B (zh) * | 2014-06-17 | 2020-02-28 | 韩国化学研究院 | 嘧啶-2,4-二胺衍生物及包含其作为有效成分的抗癌用药学组合物 |
CN105524045B (zh) * | 2014-10-22 | 2020-04-10 | 山东轩竹医药科技有限公司 | 四环类间变性淋巴瘤激酶抑制剂 |
CN106146525B (zh) * | 2015-04-10 | 2018-11-02 | 山东轩竹医药科技有限公司 | 三并环类间变性淋巴瘤激酶抑制剂 |
AU2016251253B2 (en) | 2015-04-24 | 2020-07-09 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd | Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof |
CN106699743B (zh) | 2015-11-05 | 2020-06-12 | 湖北生物医药产业技术研究院有限公司 | 嘧啶类衍生物及其用途 |
CN106220608B (zh) * | 2016-07-25 | 2018-11-27 | 安润医药科技(苏州)有限公司 | 二苯氨基嘧啶及三嗪化合物、其药用组合物及用途 |
CN107698603B (zh) * | 2016-08-09 | 2022-04-08 | 南京红云生物科技有限公司 | 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用 |
JP7094566B2 (ja) | 2016-08-29 | 2022-07-04 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | Alk阻害剤としてのアミノピリミジン類 |
CN111484484B (zh) * | 2020-04-13 | 2021-11-23 | 沈阳药科大学 | 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
GB0305929D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
JP4607879B2 (ja) * | 2003-08-15 | 2011-01-05 | ノバルティス アーゲー | 新生物疾患、炎症および免疫障害の処置に有用な2,4−ピリミジンジアミン |
GB0419161D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
ES2444222T3 (es) | 2006-07-10 | 2014-02-24 | Goji Limited | Preparación de alimentos |
CA2598893C (en) * | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
UA100846C2 (uk) * | 2006-12-08 | 2013-02-11 | Айерем Елелсі | Сполуки та композиція як інгібітори протеїнкінази |
KR101149295B1 (ko) * | 2006-12-08 | 2012-07-05 | 아이알엠 엘엘씨 | 단백질 키나제 억제제로서의 화합물 |
MX2010010968A (es) * | 2008-04-07 | 2010-10-26 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa de proteina. |
-
2012
- 2012-02-02 US US13/981,046 patent/US8703787B2/en active Active
- 2012-02-02 AU AU2012212142A patent/AU2012212142B2/en active Active
- 2012-02-02 MX MX2013008791A patent/MX2013008791A/es unknown
- 2012-02-02 ES ES12703670.5T patent/ES2543567T3/es active Active
- 2012-02-02 JP JP2013552637A patent/JP5837095B2/ja active Active
- 2012-02-02 BR BR112013019643-2A patent/BR112013019643B1/pt active IP Right Grant
- 2012-02-02 EA EA201391114A patent/EA023404B1/ru not_active IP Right Cessation
- 2012-02-02 PT PT127036705T patent/PT2670401E/pt unknown
- 2012-02-02 RS RS20150563A patent/RS54189B1/en unknown
- 2012-02-02 WO PCT/US2012/023669 patent/WO2012106540A1/en active Application Filing
- 2012-02-02 ME MEP-2015-127A patent/ME02200B/me unknown
- 2012-02-02 DK DK12703670.5T patent/DK2670401T3/en active
- 2012-02-02 SI SI201230285T patent/SI2670401T1/sl unknown
- 2012-02-02 CN CN201280007465.9A patent/CN103458881B/zh active Active
- 2012-02-02 KR KR1020137023001A patent/KR101521861B1/ko active IP Right Grant
- 2012-02-02 PL PL12703670T patent/PL2670401T3/pl unknown
- 2012-02-02 HU HUE12703670A patent/HUE025395T2/en unknown
- 2012-02-02 CA CA2824092A patent/CA2824092C/en active Active
- 2012-02-02 EP EP12703670.5A patent/EP2670401B1/en active Active
-
2015
- 2015-08-28 CY CY20151100758T patent/CY1116662T1/el unknown
- 2015-09-07 HR HRP20150946TT patent/HRP20150946T1/hr unknown
- 2015-11-30 SM SM201500300T patent/SMT201500300B/it unknown